Navigation Links
New advance announced in reducing 'bad' cholesterol
Date:12/8/2011

Scientists from the University of Leicester and University of California Los Angeles (UCLA) have announced a breakthrough advance in tackling dangerous 'bad' cholesterol in the body.

They have filed two patents for developing targeted drugs that would act as a catalyst for lowering levels of 'bad' cholesterol.

Two research papers published by the academics enhance the understanding of the regulation of low-density lipoprotein (LDL) or "bad" cholesterol.

LDL, the so-called "bad" cholesterol, is often linked to medical problems like heart disease, stroke and clogged arteries.

In the body, cells in the liver produce an LDL receptor that binds LDL and removes it from the blood, thereby lowering cholesterol levels.

However, the LDL receptors can be hindered from their mission.

The scientists found that an enzyme called IDOL has been shown to play a key and specific role in the ability of the LDL receptor to bind with 'bad' cholesterol. Therefore targeting the enzyme with drugs would assist the LDL receptors in lowering circulating cholesterol in humans.

Professor John Schwabe, Head of Biochemistry at the University of Leicester, said: "Development of a drug that interferes with IDOL's activity could help lower levels of LDL. Our research has greatly enhanced our understanding of this important process."

Prof John Schwabe, Dr Ben Goult and Dr Louise Fairall at the University of Leicester in collaboration with the University of California Los Angeles (UCLA) published their research in Genes & Development and the Proceeds of the National Academy of Science (PNAS) . The research in the UK was funded by the Wellcome Trust and in the US by NIH and the National Heart Foundation of Australia Overseas Fellowship.

The study in Genes & Development announced the first atomic structural information on IDOL and identified the E2 ligase, UBE2D that works with IDOL to degrade the LDL receptor.

In the second research article published in PNAS, the team elucidated the molecular basis for the stringent specificity of IDOL for the LDL receptor.

Professor Schwabe added: "Remarkably, IDOL only targets three proteins for degradation (all lipoprotein receptors) and this research paper greatly enhances our understanding of this specificity and identifies key residues involved in mediating this interaction.

"A potential future drug that targets IDOL could be prescribed in conjunction with statin drugs, which also cut cholesterol levels by increasing production of the LDL receptor and these two studies make considerable headway towards this. "

The universities have filed 2 patents related to the research findings.


'/>"/>
Contact: Prof. John Schwabe
js336@leicester.ac.uk
01-162-297-030
University of Leicester
Source:Eurekalert  

Related biology news :

1. UCSB scientists make advances in neuroscience and vision research
2. Roche NimbleGen and BGI develop advanced MHC region capture technology for biomedical research
3. Researchers awarded $3.2 million from NIH to pioneer advanced biomolecule discovery technology
4. Bats, dolphins, and mole rats inspire advances in ultrasound technology
5. University Hospitals Case Medical Center unlocks mystery of dystonia with advanced imaging
6. Iowa State engineers establish national panel to advance a carbon negative economy
7. Advanced Medical Care for At-Risk Newborns Nets Economic Benefits
8. Evidence for spinal membrane as a source of stem cells may advance spinal cord treatment
9. An IRB Barcelona project on computational biology receives an ERC Advanced Grant
10. Advance toward a breath test to diagnose multiple sclerosis
11. Leaf litter ants advance case for rainforest conservation in Borneo
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New advance announced in reducing 'bad' cholesterol
(Date:1/11/2016)... CHICAGO , Jan. 11, 2016  higi, ... via nearly 10,000 retail locations, web and mobile, ... than $40 million from existing investors. ... will be devoted to further innovate higi,s health ... app and web portal – including expanding services ...
(Date:1/7/2016)... -- This BCC Research report studies the global as ... identifying newer markets and exploring the expansion of the ... Includes forecast from 2015 to 2020. Use ... the expansion of the present application market for various ... technology, determine its current market size, and estimate the ...
(Date:1/6/2016)... 2016  Varam Capital, a provider of micro-finance inclusion ... deliver advanced authentication solutions to their clients. Varam supplies ... A loan of a few thousand rupees may make ... ability to purchase livestock or equipment for a small ... for a local store. ...
Breaking Biology News(10 mins):
(Date:2/3/2016)... 2016  Discovery Laboratories, Inc. (NASDAQ: DSCO ... KL4 surfactant therapies for respiratory diseases, today announced ... inducement award as a component of employment compensation ... President and Chief Executive Officer.  The award was ... 1, 2016 and granted as an inducement material ...
(Date:2/3/2016)... Ascendis Pharma A/S (Nasdaq: ASND ), ... TransCon technology to address significant unmet medical needs, today ... Leerink Partners Global Healthcare Conference Location: , Waldorf ... 2016 Time:  , 11:55am EST www.ascendispharma.com ... An audio webcast of this event will be posted ...
(Date:2/3/2016)... , Feb. 3, 2016 New ... more than $1 million for researchers in ... on health-related research that demonstrates exciting potential.   ... of funding for the New Jersey Health Foundation Research ... members at these educational institutions— Princeton University, Rutgers ...
(Date:2/3/2016)... ... 2016 , ... ProMIS Neurosciences is currently in the process ... propagating strains of Amyloid beta involved in Alzheimer’s disease. The Company plans to ... on from the first misfolded Amyloid beta target announced on Nov. 12, 2015, ...
Breaking Biology Technology: